methoxy polyethylene glycol-epoetin beta

Trials studying methoxy polyethylene glycol-epoetin beta

• phase3Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysisactive not recruitingn=228
• phase3A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.completedn=75
• phase3A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.completedn=233
• —A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysiscompletedn=144
• phase3Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjectscompletedn=456
• phase2A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysiscompletedn=175
• phase3A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patientcompletedn=391